Protalix BioTherapeutics Inc.
PLX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$208.68M
Close$
$-2.48
197.2% downside
Current Fair Value
197.2% downsideOvervalued by 197.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $208.68 Million |
|---|---|
| Enterprise Value | $190.47 Million |
| Earnings per Share | $-0.08 |
| Beta | 0.01 |
| Outstanding Shares | 79,986,325 |
Return
| Return on Equity | 26.53% |
|---|---|
| Return on Assets | 17.17% |
| Return on Invested Capital | 24.25% |
Valuation & Multiples
| P/E Ratio | 10.75 |
|---|---|
| PEG | 0.49 |
| Price to Sales | 2.55 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.36 |
| Enterprise Value to EBIT | 9.95 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$0.27
Consensus analyst estimateRevenue Estimate
$37.80 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$12.41 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 65.29% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.42%▼ 17.90% |
|---|---|
| Total Invested | $918,266▼ 97.31% |
| Investors Holding | 4▼ 105.00% |
About Protalix BioTherapeutics Inc.
CEO: Dror Bashan
